Abgenix starts Phase II colorectal cancer trial

ABGX said it started an 84-patient Phase II trial of ABX-EGF human monoclonal antibody against EGF to treat colorectal cancer. The trial is designed to assess safety and efficacy of up to 8 cycles of ...